Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date of Report: November 2, 2023
Context: The filing discloses Regulation FD information regarding upcoming clinical data presentations at the 65th American Society of Hematology (ASH) Annual Meeting (December 9–12, 2023) and provides updates on ongoing clinical trials for bitopertin and DISC-0974.
Key Financial Metrics
This Form 8-K is a current report focused on clinical developments and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Updates
Bitopertin (Erythropoietic Protoporphyria - EPP)
- Enrollment Status: Enrollment for Phase 2 BEACON (22 adults) and AURORA (75 adults) studies is complete. BEACON has been expanded to include adolescents (ages 12–18).
- BEACON Interim Data (July 5, 2023 cutoff):
- Demonstrated significant and consistent improvements in light tolerance.
- Sub-group analysis showed a correlation between protoporphyrin IX (PPIX) suppression and sunlight tolerance:
- >30% PPIX reduction: Average improvement of >10 hours in maximal weekly sunlight tolerance (n=11).
- <30% PPIX reduction: Average improvement of >4 hours (n=4).
- Upcoming ASH Presentation: Will include updated data on PPIX, photosensitivity, quality of life, safety, and a preliminary analysis of the cumulative time in light over 6 months.
- AURORA Study: Topline data expected in early 2024.
DISC-0974 (Myelofibrosis and Anemia)
- Study Status: Dose escalation is ongoing for Phase 1b/2 studies in Myelofibrosis (MF) and non-dialysis dependent chronic kidney disease (NDD-CKD).
- Upcoming ASH Presentation: Initial data from 10–20 patients in the dose-escalation phase for MF and anemia, covering safety and changes in hepcidin, iron, and hemoglobin levels.
- NDD-CKD Data: Data from the 28 mg dose cohort will be presented during the management conference call.
Guidance, Outlook, and Risks
Management Commentary: The Company will host a conference call on December 11, 2023, at 9:30 p.m. ET to review the ASH data and operational plans. An archived webcast will be available for 30 days.
Risks and Uncertainties: The filing includes a standard cautionary statement regarding forward-looking statements. Key risks include:
- Difficulty in predicting the time and cost of product development.
- Enrollment timelines for BEACON and AURORA may not be predictive of future timelines.
- Clinical trial results may not be predictive of future results or support marketing approval.
- General risks detailed in the Company's Form 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the specific dates and times for the ASH presentation and the December 11 conference call on the Company's website.
- Review the attached Exhibits 99.1, 99.2, and 99.3 for the full press release and clinical abstracts.
- Monitor the upcoming release of top-line AURORA data expected in early 2024.
- Assess the correlation between PPIX reduction and sunlight tolerance improvements in the BEACON interim analysis.
- Check subsequent filings for updates on the DISC-0974 dose-escalation cohorts and safety profiles.